洛铂联合吉西他滨治疗晚期肺鳞癌疗效分析

Efficacy of Lobaplatin Combined with Gemcitabine in the Treatment of Patients with Advanced Lung Squamous Cell Carcinoma

目的明确洛铂联合吉西他滨方案在晚期肺鳞癌中的疗效和安全性。方法入组66例晚期肺鳞癌患者分为2组,试验组30例患者接受洛铂联合吉西他滨化疗,对照组36例患者接受顺铂联合吉西他滨化疗,并比较观察2组的近期疗效和毒副反应。结果试验组有效率为36.7%,对照组为36.1%,差异无统计学意义(P>0.05);试验组Ⅲ、Ⅳ度血小板减少多于对照组,而Ⅲ、Ⅳ度恶心呕吐、乏力少于对照组,差异均有统计学意义(P均>0.05)。结论洛铂联合吉西他滨一线治疗晚期肺鳞癌近期疗效与顺铂联合吉西他滨方案相似,毒副反应方面存在差异,值得临床进一步研究。

Objective To investigate the efficacy and safety of lobaplatin combined with gemcitabine in the treatment of patients with advanced lung squamous cell carcinoma. Methods Sixty-six patients with advanced lung squamous cell carcinoma were divided into two groups,30 patients of the experimental group received lobaplatin combined with gemcitabine,and 36 patients of the control group received cisplatin combined with gemcitabine,and the short-term efficacy and toxicities were compared. Results The objective response rate in experimental group was 36. 7%,and was 36. 1% in the control group,there was no significant difference between the two groups（ P 〈0. 05）. The incidence of Ⅲ and Ⅳ degree thrombocytopenia in the experimental group was higher than that in the control group,but the incidences of Ⅲ and Ⅳ degree nausea and vomiting,anergy were lower than those in the control group（ P 〈0. 05）. Conclusion Lobaplatin combined with gemcitabine in the first-line treatment of advanced lung squamous cell carcinoma has similar effectiveness with cisplatin combined with gemcitabine,but the toxicities is different,lobaplatin combined with gemcitabine is suitable for further clinical studies.